The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C
Open accessAbstract
SUMMARY: Background Whether antidepressants prevent depression during interferon‐alpha/ribavirin treatment for hepatitis C virus infection has yet to be established. Aim To investigate the use of paroxetine in a prospective, double‐blind, placebo‐controlled study for this indication. Methods Sixty‐one hepatitis C virus‐infected patients were randomly assigned to the antidepressant, paroxetine (n = 28), or placebo (n = 33), begun 2 weeks before and continued for 24 weeks during interferon‐alpha/ribavirin treatment. Primary endpoints included development of major depression and severity of depressive symptoms measured by the Montgomery Asberg Depression Rating Scale (MADRS). Results Rates of major depression during the study were low (17%) and did not differ between groups. Nevertheless, using published MADRS cut‐off scores, the percent of subjects who met criteria for mild, moderate or severe depression during interferon‐alpha/ribavirin therapy was significantly lower in paroxetine‐ vs. placebo‐treated subjects (P = 0.02, Fisher’s exact test). Assignment to paroxetine was also associated with significantly reduced depressive symptom severity. This effect was largely accounted for by participants with depression scores above the median (MADRS > 3) at baseline in whom paroxetine was associated with a maximal reduction in MADRS scores of 10.3 (95% CI: 2.1–18.5) compared with placebo at 20 weeks (P < 0.01). Study limitations included a small sample size and high drop‐out rate. Conclusion This double‐blind, placebo‐controlled trial provides preliminary data in support of antidepressant pre‐treatment in hepatitis C virus patients with elevated depressive symptoms at baseline.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interestingly, selective serotonin (5-HT) reuptake inhibitors (SSRIs) have been shown to alleviate cytokine-induced depression (Musselman et al., 2001a, Raison et al., 2007), and depressive and anxiety symptoms appear to be most responsive, while fatigue and neurovegetative symptoms are less responsive (Capuron et al., 2002, Raison et al., 2005b, McNutt et al., 2012).”
From Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications (2013) · cites this paper as Raison et al., 2007
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C. I., Marinos, G., Gonçales, F. L., Häussinger, D., Moisés Diago, M., Carosi, G., Dhumeaux, D., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020047 · Cited by 6,386
Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M. L., Reindollar, R., Goodman, Z. D., Koury, K. J., Ling, M.-H., & Albrecht, J. K. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06102-5 · Cited by 6,027
The Fifth Edition of the Addiction Severity Index.
Mclellan, A., Kushner, H., Metzger, D., Peters, R., Smith, I. E., Grissom, G. R., Pettinati, H., & Argeriou, M. (1992) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(92)90062-s · Cited by 4,280
Handbook of Psychiatric Measures
Salzman, C. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.8.1343 · Cited by 1,172
Paroxetine for the prevention of depression induced by high-dose interferon alfa.
Musselman, D. L., Lawson, D. H., Gumnick, J. F., Manatunga, A. K., Penna, S., Goodkin, R. S., Greiner, K., Nemeroff, C. B., & Miller, A. H. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103293441303 · Cited by 1,120
Self-citationMcHutchison, J. G., Manns, M. P., Patel, K., Poynard, T., Lindsay, K. L., TREPO, C. G., Dienstag, J. L., Lee, W. M., Mak, C., Garaud, J., et al. (2002) · Gastroenterology · doi:10.1053/gast.2002.35950 · Cited by 969
Davis, G. L., Wong, J. B., McHutchison, J. G., Manns, M. P., Harvey, J., & Albrecht, J. K. (2003) · Hepatology · doi:10.1053/jhep.2003.50364 · Cited by 819
Research works printed but not linked: 3
- 10.1176/appi.ps.57.4.570 · DOI
- Anonymous, 2005, Physicians’ Desk Reference
- Jacobson IM, 2005, Weight‐based ribavirin (WBD) increases sustained viral response (SVR) in patients with chronic hepatitis C (CHC): final results of the WIN‐R study, a US community based trial, Hepatol, 1, 749A
Cited by
Sorted by citations
PRACTICE GUIDELINE FOR THE Treatment of Patients With Major Depressive Disorder
Gelenberg, A. J., Freeman, P. B., Markowitz, J. C., Rosenbaum, J. F., Thase, M. E., Trivedi, M. H., & Rhoads, R. S. (2010) · Cited by 1,372
Immune system to brain signaling: Neuropsychopharmacological implications
Capuron, L., & Miller, A. H. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.01.014 · Cited by 1,195
Self-citationInflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications
Felger, J. C., & Lotrich, F. E. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.04.060 · Cited by 1,180
Haroon, E., Raison, C. L., & Miller, A. H. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.205 · Cited by 1,000
Self-citationThe Link between Depression and Chronic Pain: Neural Mechanisms in the Brain
Sheng, J., Shui, L., Wang, Y., Cui, R., & Zhang, X. (2017) · Neural Plasticity · doi:10.1155/2017/9724371 · Cited by 852
Metadata
- Authors
- RAISON, C. L., WOOLWINE, B. J., DEMETRASHVILI, M. F., BORISOV, A. S., WEINREIB, R., STAAB, J. P., ZAJECKA, J. M., BRUNO, C. J., HENDERSON, M. A., REINUS, J. F., EVANS, D. L., ASNIS, G. M., & MILLER, A. H.
- Affiliations
- Emory University (US)
- University of Pennsylvania (US)
- Rush University Medical Center (US)
- Kaiser Permanente (US)
- Albert Einstein College of Medicine (US)
- Corresponding author
- MILLER, A. H.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2007-03-20
- Volume
- 25
- Issue
- 10
- Pages
- 1163-1174
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W1482765914
- Cited by
- 142
- References
- 60
- Citations by year
- 2025: 1 · 2024: 1 · 2022: 4 · 2020: 4 · 2019: 3 · 2018: 3 · 2017: 3 · 2016: 3 · 2015: 11 · 2014: 8 · 2013: 23 · 2012: 17
- FWCI
- 10.96
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Alimentary Pharmacology & Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Pfizer
- National Institutes of Health
- National Institute of Mental Health (MH-00680, K23MH064619, MH 60723, MH 64619, R01MH060723, MH060723)
- National Center for Research Resources (M01-RR00039, M01RR000039)
- NIH Clinical Center
- Topics
- Health Sciences › Medicine › Hepatology › Hepatitis C virus research
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- paroxetine, antidepressant prophylaxis, depression prevention, interferon-alpha, ribavirin, hepatitis C, depressive symptoms, antiviral therapy adverse effects, Montgomery-Asberg Depression Rating Scale
- MeSH terms
- Adolescent, Adult, Aged, Antiviral Agents, Depressive Disorder, Major, Major Depressive Disorder, Double-Blind Method, Female, Humans, Male, Middle Aged, Ribavirin, Interferon-alpha, Paroxetine, Hepatitis C, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
